Cognition Therapeutics, Inc. (CGTX) Shareholder Equity
- 2026-06-30: Common Stock, Value, IssuedUSD $95.00K; Additional Paid in CapitalUSD $240.08M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD (m); Retained Earnings (Accumulated Deficit)USD $-207.15M.
- 2026-03-31: Common Stock, Value, IssuedUSD $90.00K; Additional Paid in CapitalUSD $233.04M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD (m); Retained Earnings (Accumulated Deficit)USD $-203.22M.
- 2025-12-31: Common Stock, Value, IssuedUSD $90.00K; Additional Paid in CapitalUSD $232.83M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD (m); Retained Earnings (Accumulated Deficit)USD $-198.65M.
- 2025-09-30: Common Stock, Value, IssuedUSD $88.00K; Additional Paid in CapitalUSD $231.75M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD (m); Retained Earnings (Accumulated Deficit)USD $-195.30M.
Cognition Therapeutics, Inc. Shareholder Equity
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Common Stock, Value, Issued USD | Additional Paid in Capital USD | Accumulated Other Comprehensive Income (Loss), Net of Tax USD | Retained Earnings (Accumulated Deficit) USD | Stockholders' Equity Attributable to Parent USD | APIC, Share-based Payment Arrangement, Increase for Cost Recognition USD | Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt USD | Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs USD |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $95.00K | $240.08M | (m) | $-207.15M | $33.02M | 3 month · $319.00K | (m) | (m) |
| 2026-03-31 | $90.00K | $233.04M | (m) | $-203.22M | $29.91M | 3 month · $330.00K | (m) | (m) |
| 2025-12-31 | $90.00K | $232.83M | (m) | $-198.65M | $34.27M | 12 month · $2.09M | (m) | (m) |
| 2025-09-30 | $88.00K | $231.75M | (m) | $-195.30M | $36.53M | 3 month · $522.00K | (m) | (m) |
| 2025-06-30 | $65.00K | $197.34M | (m) | $-190.37M | $7.03M | 3 month · $621.00K | (m) | (m) |
| 2025-03-31 | $62.00K | $195.85M | (m) | $-183.64M | $12.27M | 3 month · $586.00K | (m) | (m) |
| 2024-12-31 | $60.00K | $193.85M | (m) | $-175.16M | $18.75M | 12 month · $82.00K | (m) | (m) |
| 2024-09-30 | $41.00K | $181.76M | (m) | $-167.32M | $14.48M | 3 month · $896.00K | (m) | (m) |
| 2024-06-30 | $40.00K | $180.35M | (m) | $-157.38M | $23.01M | 3 month · $1.15M | (m) | (m) |
| 2024-03-31 | $40.00K | $179.16M | (m) | $-150.34M | $28.86M | 3 month · $1.17M | (m) | (m) |
| 2023-12-31 | $32.00K | $165.83M | $-195.00K | $-141.19M | $24.47M | 12 month · $4.35M | (m) | (m) |
| 2023-09-30 | $30.00K | $162.14M | $-196.00K | $-133.05M | $28.93M | 3 month · $1.07M | (m) | (m) |
| 2023-06-30 | $30.00K | $160.85M | $-196.00K | $-126.30M | $34.39M | 3 month · $1.02M | (m) | (m) |
| 2023-03-31 | $29.00K | $157.52M | $-195.00K | $-121.57M | $35.78M | 3 month · $1.19M | (m) | (m) |
| 2022-12-31 | $29.00K | $155.82M | $-199.00K | $-115.40M | $40.25M | 12 month · $3.57M | (m) | (m) |
| 2022-09-30 | $24.00K | $149.72M | $-201.00K | $-110.22M | $39.32M | 3 month · $777.00K | (m) | (m) |
| 2022-06-30 | $22.00K | $147.67M | $-200.00K | $-103.59M | $43.90M | 3 month · $892.00K | (m) | (m) |
| 2022-03-31 | $22.00K | $146.76M | $-197.00K | $-97.84M | $48.74M | 3 month · $1.00M | (m) | (m) |
| 2021-12-31 | $22.00K | $145.45M | $-198.00K | $-94.00M | $51.27M | 12 month · $5.18M | 12 month · $-14.46M | 12 month · $7.78M |
| 2021-09-30 | $1.00K | $142.00K | $-196.00K | $-86.67M | $-86.72M | 3 month · $72.00K | (m) | (m) |
| 2021-06-30 | (m) | (m) | (m) | (m) | $-83.68M | 3 month · $94.00K | 3 month · $-14.46M | (m) |
| 2021-03-31 | (m) | (m) | (m) | (m) | $-67.85M | 3 month · $98.00K | (m) | (m) |
| 2020-12-31 | $1.00K | $222.00K | $-187.00K | $-68.22M | $-68.18M | 12 month · $475.00K | (m) | (m) |
| 2020-09-30 | (m) | (m) | (m) | (m) | $-66.49M | 3 month · $129.00K | (m) | (m) |
| 2020-06-30 | (m) | (m) | (m) | (m) | $-64.51M | 3 month · $88.00K | (m) | (m) |
| 2020-03-31 | (m) | (m) | (m) | (m) | $-61.97M | 3 month · $125.00K | (m) | (m) |
| 2019-12-31 | (m) | (m) | (m) | (m) | $-58.42M | (m) | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |